Lauren M. Green

Articles

Immuno Combos Gain Steam in Blood Cancers

December 2nd 2016

Checkpoint blockade immunotherapies that have moved quickly from the development stage to clinical use in a range of solid tumors are also being explored in hematologic malignancies.

Immunotherapy Combo Regimens on Horizon in Lymphoma

November 12th 2016

Nivolumab (Opdivo) may be the only checkpoint inhibitor that is approved by the FDA as a treatment of patients with Hodgkin lymphoma, but other immunotherapies—alone and in combination with other novel agents—are emerging in other indications.

Patient Selection Critical to Optimizing Neoadjuvant Chemo in Ovarian Cancer

November 11th 2016

As a treatment of patients with advanced ovarian cancer, evidence has shown that neoadjuvant chemotherapy has reduced mortality and improved quality of life. However, oncologists are still challenged at how to deploy this treatment approach in clinical practice.

Studies Confirm Rolapitant Reduces CINV in Breast and Gynecologic Cancers

August 18th 2016

Additional findings from 2 studies of rolapitant (Varubi) for the prevention of CINV are providing further evidence of the efficacy of the long-acting NK-1 receptor antagonist.

Expert Shares How Neoadjuvant Trials for TNBC Will Improve Treatment Decisions

July 25th 2016

Recent findings from clinical trials exploring neoadjuvant treatment in patients with triple-negative breast cancer may provide answers to several questions surrounding early-stage disease.

Steroid Mouthwash May Prevent Stomatitis in Some Breast Cancer Patients

July 21st 2016

A study of women treated with the mTOR inhibitor everolimus (Afinitor) plus exemestane for their advanced breast cancer found that daily use of a steroid-based mouthwash markedly decreased the incidence and severity of stomatitis.

Individualizing Care for Elderly Patients With Localized Head and Neck Cancer

July 13th 2016

Although paradigms for treating older patients with head and neck cancer are not well defined, advancements in targeted and immunotherapies and less toxic radiation regimens suggest that physicians can aim for a more individualized approach to treating this patient population.

ADT Increases Risk for Depression in Elderly Men With Localized Prostate Cancer

June 21st 2016

Although androgen deprivation therapy has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether it causes clinically significant depression.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction

June 7th 2016

Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.

Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer

June 6th 2016

Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.

Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment

June 5th 2016

Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.

Study Confirms Adjuvant Intraperitoneal Chemotherapy Is Beneficial and Well Tolerated

June 4th 2016

Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.

Finding the Right Dose: Sublingual Fentanyl Spray for Breakthrough Cancer Pain

April 28th 2016

West Cancer Center researchers developed a best nursing practice protocol for titration of fentanyl sublingual spray, which is the most recently approved transmucosal immediate-release fentanyl formulation.

When a Symptom Intervention Works, Why Not Use It?

April 28th 2016

When oncology nurses move proactively to learn more about and use proven effective green-lighted interventions like exercise and muscle relaxation in their daily practice, it can go a long way.

Moving Proactively to Support Patients With EGFR Inhibitor-Related Dermatologic AEs

April 28th 2016

Developing a skin rash as a result of EGFR-inhibitor targeted therapy often signals that the drug is working, but for patients who experience these serious dermatologic adverse events, it may become so intolerable that they will scale back or even discontinue anticancer medications that could prolong their survival.

Two Genetic Variants May Signal Which Survivors Are at Highest Risk for Breast Cancer After Chest Radiation

April 18th 2016

Chest radiotherapy to treat a childhood cancer is a well-established risk factor for developing breast cancer in adulthood

ACS Publishes New Guideline for Head and Neck Cancer Survivorship Care

March 28th 2016

An expert panel has developed clinical practice guidelines for the management of head and neck cancer survivors.

Excessive Imaging in Early-Stage Breast Cancer Detailed in Study

March 17th 2016

A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.

Cognitive Complaints After Cancer Treatment Extend Beyond “Chemo Brain”

February 17th 2016

Although patients and survivors often complain of â€œchemobrainâ€ during and after their cancer treatment, it turns out that there are multiple factors behind the cognitive decline many survivors experience.

Results for Lu-Dotatate in Patients With Midgut NETs Continue to Impress

January 19th 2016

For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.